Results 71 to 80 of about 38,381 (226)

Distinct Brain Drivers and Shared Cerebello–Cortical Input in ADCY5 and SGCE Hyperkinetic Movements

open access: yesMovement Disorders, EarlyView.
Resting‐state fMRI and effective connectivity revealed distinct cerebellar–basal ganglia–cortical interactions in ADCY5 (MxMD‐ADCY5) and SGCE (MYC/DYT‐SGCE) related movement disorders. The cerebellum modulated cortex directly in MYC/DYT‐SGCE, but indirectly via basal ganglia‐cerebellar projections in MxMD‐ADCY5, which also showed reduced subthalamic ...
Clément Tarrano   +33 more
wiley   +1 more source

Botulinum Toxin and Its Contribution to the Treatment of Masseteric Hypertrophy

open access: yesČeská Stomatologie a Praktické Zubní Lékařství, 2005
With discovery and use of botulinum toxin masseteric hypertrophy has become treatable in a minimal invasive way. The authors discuss the masseteric hypertrophy as such as well as they describe a technique of clinical application of botulinum toxin in its
R. Jurkovič, P. Macák
doaj  

Phenotyping Overactive Bladder – Part 2: Can Management be Improved by Phenotyping, and Targeting Therapy According to Urgency Type and Other Characteristics? ICI‐RS 2025

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Management of overactive bladder (OAB) has a stepwise approach in adults and children. This does not account for individual patient variations, which may explain suboptimal outcomes in many patients. Distinct OAB profiles, based on patient characteristics, symptoms, urodynamic findings and imaging have been discussed in Part 1 ...
Michel Wyndaele   +9 more
wiley   +1 more source

The Effect of Different Doses of Botulinum Toxin on Masseter Muscle in Patients with Bruxism.

open access: yesErbil Dental Journal, 2022
Background and Objectives: Botulinum toxin type A is produced by clostridium botulinum. It acts by inhibiting the release of acetylcholine from cholinergic neurons.
Kawa F. Dizaye, Sarezh Jamal Jalal
doaj  

β3‐Adrenoceptor Agonists for Neurogenic Lower Urinary Tract Dysfunction: Evidence and Clinical Rationale for First‐Line Therapy

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley   +1 more source

Should We Consider Sacral Nerve Stimulation as a Treatment for Neurogenic Lower Urinary Tract Dysfunction? ICI‐RS 2025

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Aims To explore the boundary of clinical use of sacral nerve stimulation (SNS) in neurogenic lower urinary tract dysfunction (NLUTD), identifying barriers to approval and early‐impact research questions. Methods This review is derived from a proposal discussion at the International Consultation on Incontinence‐Research Society in Bristol in ...
Marcus J. Drake   +6 more
wiley   +1 more source

What Is Required for AI to Improve the Assessment and Treatment of Patients With Lower Urinary Tract Dysfunction? ICI‐RS 2025

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Artificial intelligence (AI) is poised to improve the diagnosis and management of lower urinary tract dysfunction (LUTD). Its effective deployment requires prioritization, regulatory oversight, rigorous validation, and clinician and patient engagement.
Glenn T. Werneburg   +15 more
wiley   +1 more source

Botulinum toxin in management of back pain

open access: yesQuality in Sport
Introduction The botulinum toxin is a widely used therapeutic agent.  It is used for aesthetic reasons in treatment of glabellar wrinkles. Therapeutic indications include cervical dystonia, hyperhidrosis or migrenes.
Blanka Łuczak   +9 more
doaj   +1 more source

What Role Does the Central Nervous System Play in Refractory LUTS, and What Are the Therapeutic Implications? ICI‐RS 2025

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Aims While many patients with lower urinary tract symptoms (LUTS) improve by treating peripheral causes, a substantial proportion continue to experience symptoms despite apparently successful interventions. Central nervous system (CNS) mechanisms could potentially contribute to persisting symptoms after the initial peripheral cause has been ...
Mathijs M. de Rijk   +7 more
wiley   +1 more source

Cosmetic use of botulinum toxin type A in the elderly

open access: yesClinical Interventions in Aging, 2007
Christine M ChengDepartment of Clinical Pharmacy, University of California, San Francisco, CA, USAAbstract: Botulinum toxin type A injections are one of the most popular cosmetic procedures for diminishing the appearance of facial lines caused by ...
Christine M Cheng
doaj  

Home - About - Disclaimer - Privacy